119273-81-3Relevant articles and documents
-
Haworth,Woodcock
, p. 95 (1947)
-
BRD4-JAK2 INHIBITORS
-
Page/Page column 41-42, (2020/03/29)
Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I, II, and II.
Development of a practical synthesis of an aminoindanol-derived m1 agonist
Hansen, Marvin M.,Borders, Sandra S.K.,Clayton, Marcella T.,Heath, Perry C.,Kolis, Stanley P.,Larsen, Samuel D.,Linder, Ryan J.,Reutzel-Edens, Susan M.,Smith, Justin C.,Tameze, Sheila L.,Ward, Jeffrey A.,Weigel, Leland O.
experimental part, p. 198 - 208 (2010/04/22)
An efficient and scalable synthesis of the clinical candidate 1 is described. The first-generation synthesis built the enantioenriched nitro-aminoindanol core from 6-nitroindanone using a five-step literature route. The second-generation route used a safe aromatic nitration protocol in the presence of the unprotected alcohol to afford the requisite nitro-aminoindanol in one step. Challenges addressed in the remainder of the synthesis include a nitro group reduction to afford ppm levels of unreacted Ar-NO2 (a mutagen) and a novel amidine formation under mild conditions via DMAP/K2CO3-promoted reaction with a thioimidate-activated amide. A convenient protocol for freebasing the API was provided by stirring with solid K2CO3 and monitoring disappearance of HI by reverse-phase HPLC.
